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OBJECTIVES The study evaluated the relationship between plasma cardiotrophin-1 (CT-1) concentration
and left ventricular (LV) mass in dilated cardiomyopathy (DCM) patients with congestive
heart failure (CHF).
BACKGROUND Cardiotrophin-1 is a newly identified member of the interleukin-6 (IL-6) family of cytokines
and one of the endogenous ligands for gp130 signaling pathways in the heart, and it has
potent hypertrophic and survival effects on cardiac myocytes. However, the clinical signifi-
cance of CT-1 is poorly understood.
METHODS We measured the plasma CT-1 level in 51 consecutive patients with DCM. Patients were
classified into two groups: small LV mass index group and large LV mass index group, based
on the median level of LV mass index.
RESULTS The plasma CT-1 level was increased in DCM patients with the severity of CHF and was
significantly higher in the large LV mass group than in the small LV mass group, despite the
absence of a difference in LV ejection fraction between the two groups. In addition, there was
a significant positive correlation between the plasma CT-1 level and the LV mass index (r 
0.627, p  0.0001). According to stepwise multivariate analyses among hemodynamic and
neurohumoral factors, a high plasma CT-1 level showed an independent and significant
positive relationship with a large LV mass index in patients with DCM.
CONCLUSIONS These results indicate that the plasma CT-1 level is increased in patients with DCM and is
significantly correlated with the LV mass index, suggesting that CT-1 plays an important role
in structural LV remodeling in patients with DCM. (J Am Coll Cardiol 2001;38:1485–90)
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Neurohumoral factors including cytokines are activated and
play an important role in the pathophysiology and the
prognosis in congestive heart failure (CHF) (1–10). In
addition, most of these factors induce cardiac hypertrophy,
which is initially an adaptation to pressure overload and/or
volume overload but ultimately leads to CHF.
Cardiotrophin-1 (CT-1), is a member of the interleukin-6
(IL-6) family of cytokines, which was originally discovered as
a factor that can induce hypertrophy of cardiac myocytes
(11–13). The CT-1 mRNA is widely expressed in various
tissues including the heart, kidney, skeletal muscle, and liver
(14), and CT-1 is increased in plasma in patients with CHF
(15). Cardiotrophin-1 binds with the gp130/leukemia inhibi-
tory factor receptor heterodimer and induces ventricular hy-
pertrophy in vivo and in vitro (16,17). Moreover, the aug-
mented expression of CT-1 has been detected in the ventricle
of genetically hypertensive rats where it may contribute to
ongoing hypertrophic response (18). Similarly, overexpression
has been reported of both CT-1 and gp130 in the rat ventricle
after myocardial infarction and during experimental acute
Chagasic cardiomyopathy (19,20). Moreover, CT-1-induced
cardiomyocyte hypertrophy in vitro resembles the hypertrophic
pattern observed in volume overload hypertrophy in human
CHF (17,21,22). Taken together, CT-1 plays an important
role in structural remodeling that characterizes CHF related to
volume overload such as dilated cardiomyopathy (DCM).
Talwar et al. (15) reported that plasma CT-1 levels are
increased in patients with CHF; however, the plasma CT-1
concentration in patients with DCM, which is characterized by
volume overload, remains unknown. Recently, we developed a
sensitive and specific radioimmunoassay for human CT-1 (23).
Therefore, in the present study, we evaluated the relationship
between plasma CT-1 level and the left ventricular (LV) mass
index and neurohumoral factors such as norepinephrine and
angiotensin II, which can stimulate CT-1 production in vitro,
in patients with DCM.
METHODS
Patients. The study population consisted of 51 consecutive
CHF patients with dilated cardiomyopathy (DCM) (left
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ventricular ejection fraction [LVEF] 45%). The diagnosis
of DCM was based on patient history, physical examina-
tion, electrocardiogram, chest radiography, echocardiogra-
phy, left ventriculography and coronary angiography. All
patients were free of hypertension, ischemic heart disease,
valvular heart disease, congenital malformations of the heart
or vessels, and intrinsic pulmonary, renal, or metabolic
diseases. Endomyocardial biopsies were obtained to rule out
secondary cardiomyopathies caused by viral or other infec-
tious myocarditis, sarcoidosis, amyloidosis or other meta-
bolic heart disease. Patients with secondary DCM were
excluded from the study. Among the 51 patients with
DCM, there were no patients with diabetes mellitus or
hyperlipidemia. The subjects were 33 men and 18 women
ranging in age from 17 to 78 years (mean: 55 years).
Thirty-three patients were classified according to the stan-
dards of the New York Heart Association (NYHA) as
functional class II, 14 patients as functional class III, and
four patients as class IV. At entry into the study, 44 patients
were being treated with furosemide, 23 with spironolactone,
32 with angiotensin-converting enzyme (ACE) inhibitors,
35 with digitalis, 14 with beta-blockers and 3 with angio-
tensin type-1 receptor blockers. Most drugs had been
administered for more than two months. We also selected
16 control subjects (aged 26 to 75 years; mean, 54 years).
Among the 16 control subjects, there were no patients with
diabetes mellitus, hyperlipidemia or hypertension. Informed
consent was obtained from all patients before participating
in the study, and the protocol was approved by the Human
Investigations Committee of our institution.
Study protocol. All patients were premedicated with an
oral dose of diazepam (5 mg) and rested in bed in the supine
position for at least 20 min. Right-sided cardiac catheter-
ization was performed using a 7F Swan-Ganz catheter.
Blood samples for measuring plasma levels of CT-1, IL-6,
brain natriuretic peptide (BNP), norepinephrine, angioten-
sin II and endothelin-1 were collected from the femoral
artery. Left ventriculography performed by contrast medium
was analyzed for LVEF and left ventricular (LV) volume
after obtaining hemodynamic measurements and blood
samples.
The M-mode echocardiography was also performed with
two-dimensional monitoring using a Sonolayer phased-
array sector scanner (model SSH-160A, Toshiba, Tokyo,
Japan) in a blinded fashion within one week before cathe-
terization. Left ventricular mass was calculated according to
the American Society of Echocardiography recommenda-
tions (24) but was then corrected according to the sugges-
tions of Devereux et al. (25). Patients were classified into
two groups: small LV mass index group and large LV mass
index group, based on the LV mass index. The cutoff level
was the median value (163 g/m2) for the LV mass index.
Measurements of neurohumoral factors and CT-1.
Blood for measuring plasma levels of CT-1, IL-6, BNP and
endothelin-1 was transferred to a chilled tube containing
EDTA (1 mg/ml) and aprotinin (500 kallikrein inactivator
U/ml) and then centrifuged at 3,000 rpm for 15 min at 4°C.
The plasma thus obtained was stored at 30°C until
assayed. Plasma CT-1 levels were measured by a sensitive
and specific RIA for human CT-1, as previously reported
(23). In this RIA, recombinant full-length human CT-1
was used for both the standard and the tracer. The working
range of this RIA was 120 to 8,300 fmol/ml. The coefficient
of variation (CV) values for within- and between-assay
values were 4.1% to 5.6% (n  10) and 3.3% to 8.4% (n 
5), respectively. This RIA did not cross-react with IL-6,
IL-11, leukemia inhibitory factor, ciliary neurotrophic fac-
tor or oncostatin M (23).
The plasma IL-6 level was determined using a commer-
cially available immunoassay (Quantikine HS, R&D Sys-
tems, Minneapolis, Minnesota), as previously reported (10).
Plasma BNP concentrations were measured with a specific
immunoradiometric assay kit for human BNP (Shionogi,
Osaka, Japan), as previously reported (7). The plasma
endothelin-1 level was determined using an antibody
against synthetic endothelin-1 (Peninsula Laboratories,
Belmont, California) and 125I-labeled endothelin-1 (Amer-
sham Japan, Tokyo), as previously reported (3). Plasma
angiotensin II levels were measured using an RIA with a
specific antibody directed against synthetic angiotensin II,
as reported previously (26). The plasma norepinephrine
concentration was measured by high-performance liquid
chromatography.
Statistical analysis. All results are expressed as the mean
SEM. Univariate analysis was performed using the Student
t test. Categorical data were compared against a chi-squared
distribution. Comparisons between multiple groups were
determined by one-way analysis of variance (ANOVA) with
the Scheffe’s F test. To evaluate the factors regulating the
LV mass index in patients with DCM, univariate and
stepwise multivariate analyses were used among the 15
parameters. Linear regression analysis was employed to
determine the relationship between continuous variables. A
p value 0.05 was regarded as significant.
RESULTS
Hemodynamic and neurohumoral data. Patients were
divided into two groups according to symptoms, and they
were analyzed for hemodynamic and neurohumoral data
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1486 Tsutamoto et al. JACC Vol. 38, No. 5, 2001
Cardiotrophin-1 and Left Ventricular Mass November 1, 2001:1485–90
(Table 1). Left ventricular end-diastolic pressure was sig-
nificantly higher in severe CHF patients (NYHA functional
class III or IV) than in mild CHF patients (NYHA
functional class II). The LVEF was significantly lower in
severe CHF than in mild CHF patients. Neurohumoral
factors such as plasma levels of BNP, norepinephrine,
endothelin-1, IL-6 and CT-1 were significantly higher in
severe CHF patients than in mild CHF patients.
Plasma concentration of CT-1 and LV mass index in
patients with DCM. Plasma CT-1 level was increased
with the severity of CHF in DCM patients compared with
that in control subjects (Fig. 1). There were no differences in
heart rate, mean arterial blood pressure, LV end-diastolic
pressure and LVEF between the small LV mass index group
and the large LV mass index group, and there were also no
differences in plasma levels of BNP, norepinephrine and
treatments (Table 2). Plasma levels of CT-1, IL-6 and
endothelin-1, and LV end-diastolic volume index were
significantly higher in the large LV mass group than in the
small LV mass group (Fig. 2).
Comparison between the plasma CT-1 level and other
neurohumoral factors. In 51 CHF patients with DCM,
there was no significant correlation between plasma level of
CT-1 and plasma levels of norepinephrine (r  0.097),
angiotensin II (r  0.035), endothelin-1 (r  0.036), BNP
(r  0.064), and IL-6 (r  0.071).
Relationship between the plasma CT-1 level and LV
mass index. Table 3 shows the results of univariate and
multivariate analyses assessing the factors regulating the LV
mass index in 51 patients with CHF. According to stepwise
multivariate analyses, a high plasma CT-1 (p 0.0001) and
LV end-diastolic volume index (p  0.0001) were signifi-
cant independent predictors of a large LV mass index in
patients with DCM. Figure 3 shows the correlation between
the plasma CT-1 concentration and the LV mass index (r
0.627; p  0.0001).
DISCUSSION
The results of this study demonstrate that the plasma CT-1
level increases with the severity of CHF in DCM patients
compared with that in control subjects. Furthermore, we
demonstrate for the first time that the plasma CT-1 level
correlates with the LV mass index in patients with DCM,
which is characterized by volume overload, suggesting that
CT-1 plays an important pathophysiological role of LV
remodeling and/or LV hypertrophy in patients with DCM.
Relationship between the CT-1 and structural LV re-
modeling. Wollert et al. (17,21) reported that hypertrophic
response induced by CT-1 signaling through gp130 is distinct
from the hypertrophic response seen after stimulation of
G-protein coupled receptors, both on a morphological and a
molecular level. Adrenergic agonists, endothelin-1, and angio-
tensin II induce a rather uniform increase in cardiomyocyte
size, but CT-1 induces a predominant increase in cell length
with the addition of new sarcomeric units in series but no
concomitant increase in cell width. In the present study,
although there was no correlation between plasma levels of
norepinephrine, endothelin-1, and angiotensin II and LV mass
Table 1. Hemodynamic and Neurohumoral Data
Mild CHF
(n  33)
Severe CHF
(n  18) p Value
HR (beats/min) 75  3.0 87.2  5.0 NS
MBP (mm Hg) 85.6  2.6 80.9  4.3 NS
Cardiac index (l/min/m2) 2.6  0.1 2.5  0.1 NS
LVEF (%) 32.1  1.0 25.3  2.3 0.0017
LV end-diastolic pressure (mm Hg) 9.5  0.8 23.0  1.5 0.0001
LV end-diastolic volume index (ml/m2) 198  11 238  20 0.06
Norepinephrine (pg/ml) 391  40 591  98 0.03
Angiotensin II (pg/ml) 22.7  8.1 67.4  40 0.16
Endothelin-1 (pg/ml) 2.6  0.12 4.1  0.4 0.0002
BNP (pg/ml) 128  21 557  95 0.0001
IL-6 (pg/ml) 2.4  0.3 4.1  0.7 0.022
CT-1 (fmol/ml) 544  21 656  53 0.026
Mild CHFNYHA (New York Heart Association) functional class II; Severe CHFNYHA functional class III or IV; HR
heart rate; MBP  mean arterial blood pressure; LVEF  left ventricular ejection fraction; LV  left ventricular; BNP  brain
natriuretic peptide; IL-6  interleukin-6; CT-1  cardiotrophin-1.
Figure 1. Plasma cardiotrophin-1 (CT-1) concentrations in control sub-
jects and in congestive heart failure (CHF) patients with dilated cardio-
myopathy. Mild CHFNew York Heart Association (NYHA) functional
class II; severe CHF  NYHA functional class III–IV. *p  0.05 versus
the value of control subjects; #p  0.05 versus the value of the mild CHF.
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index (data not shown), there was a significant positive corre-
lation between plasma CT-1 level and LV mass in patients
with DCM. Therefore, our human data are consistent with the
experimental studies including the results by Wollert et al.
(17,21). Overexpression has been reported of both CT-1 and
gp130 in the rat ventricle after myocardial infarction and
during experimental acute Chagasic cardiomyopathy (19,20),
suggesting that CT-1 contributes to LV remodeling in patients
with myocardial infarction and Chagas’ disease, which are
characterized by volume overload. Moreover, there was a
positive correlation between ventricular CT-1 mRNA and LV
mass index in a canine model of pacing-induced experimental
CHF that closely mimics human DCM (27). Therefore, these
results (19,20,27) also support our data of a positive correlation
between plasma CT-1 level and LV mass in patients with
DCM.
Relationship between the plasma CT-1 level and LV
mass index in patients with DCM. The CT-1 mRNA is
widely expressed in various tissues, including heart, kidney,
skeletal muscle and liver (14), and CT-1 is increased in
plasma in patients with CHF (15); however, both the source
and the clearance of increased plasma CT-1 remain un-
known. It has been shown that gp130, which mediates the
action of CT-1, is abundantly expressed in the heart (28),
suggesting that elevated circulating CT-1 contributes to LV
hypertrophy. However, further studies are needed to clarify
the source and clearance of plasma CT-1 in patients with
CHF.
Neurohumoral factors such as norepinephrine and angio-
tensin II, which can stimulate CT-1 production in vitro
(29,30), were increased in the present study. However, there
was no correlation between plasma CT-1 concentration and
plasma levels of these vasoconstrictors. Therefore, these
neurohumoral factors may not be the main cause of in-
creased plasma CT-1 in patients with DCM. According to
stepwise multivariate analyses, a high plasma CT-1 was a
significant independent predictor of a large LV mass index
Table 2. Patient Characteristics
Small LVMI
Group
(n  25)
Large LVMI
Group
(n  26) p Value
Age (yrs) 57.9  3.2 52.2  2.0 NS
Gender (male/female) 18/7 13/13 NS
NYHA functional class 2.3  0.1 2.5  0.1 NS
HR (beats/min) 80  2.8 78  4.7 NS
MBP (mm Hg) 86.6  3.0 81.4  3.3 NS
PCWP (mm Hg) 10.0  1.1 10.8  1.7 NS
LV end-diastolic pressure (mm Hg) 13.3  1.4 15.2  2.0 NS
LV end-diastolic volume index (ml/m2) 176  10 247  15 0.0003
LV mass index (ml/m2) 136  3.8 205  6.2 0.0001
LVEF (%) 31.5  1.5 27.9  1.4 NS
CT-1 (fmol/ml) 507  21 658  35 0.0011
BNP (pg/ml) 233  64 324  66 NS
IL-6 (pg/ml) 2.3  0.3 3.7  0.6 0.03
Norepinephrine (pg/ml) 414  46 741  291 NS
Endothelin-1 (pg/ml) 2.7  0.2 3.5  0.3 0.045
Angiotensin II (pg/ml) 12.8  1.9 63.3  29 0.09
Treatments
Furosemides 20 24 NS
Spironolactone 10 13 NS
Digitalis 17 18 NS
ACE inhibitors 16 16 NS
Beta-blockades 4 10 NS
ARB 0 3 NS
ACE  angiotensin-converting enzyme; ARB  angiotensin II type-1 receptor blockers; BNP  brain natriuretic peptide;
CT-1  cardiotrophin-1; HR  heart rate; IL-6  interleukin-6; Large LVMI group  LVMI 163 g/m2; LV  left
ventricular; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; MBP  mean arterial blood
pressure; PCWP  pulmonary capillary wedge pressure; Small left ventricular mass index (LVMI) group  LVMI 163 g/m2.
Figure 2. Plasma cardiotrophin-1 (CT-1) concentrations in patients with
dilated cardiomyopathy. Patients were classified into two groups: small left
ventricular mass index (LVMI) group and large LVMI, based on the
median value of LV mass index. *p  0.01 versus the value in the small
LVMI group.
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in patients with DCM, suggesting the important role of
CT-1 in LV remodeling in patients with DCM. Although
the cause and effect of this relationship remain unknown, a
previous study has reported ventricular hypertrophy in
transgenic models that overexpress IL-6 and IL-6 receptor
(31) and the possibility of increased gp130 expression in
CHF, suggesting that CT-1 may stimulate myocardial
hypertrophy in patients with DCM. Recently, we reported
that plasma IL-6 level was an independent prognostic
predictor in patients with CHF including DCM (32);
however, further studies are needed to evaluate the cause
and effect of this relationship and the relation between
plasma CT-1 and the prognosis of DCM patients. In
addition, further studies are also needed to evaluate the
plasma CT-1 and LV mass index in patients with other
etiologies such as hypertension, ischemic heart disease and
hypertrophic cardiomyopathy.
Conclusions. The plasma CT-1 level increases with the
severity of CHF in DCM patients compared with that in
control subjects, and it correlates with the LV mass index in
patients with DCM, which is characterized by volume
overload, suggesting that CT-1 has an important patho-
physiological role in LV remodeling and/or LV hypertrophy
in patients with DCM.
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